Merck to Buy Insulin Developer SmartCells

WHITEHOUSE STATION, NJ - Drugmaker Merck & Co. says it will buy insulin developer SmartCells in a deal that may exceed $500 million if development and regulatory milestones are met.

Merck says SmartCells is a private company developing a form of insulin that responds only in a specific glucose concentration range. If successful, the treatment may lower the risk of low blood sugar compared to standard insulins and improve control over both fasting and post-meal glucose levels.

SmartCells CEO Dr. Todd Zion developed the company's core technology at the Massachusetts Institute of Technology.

41 NBC News On Demand

41NBC.com